Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy of Rivaroxaban for Thromboprophylaxis in Idiopathic Membranous Nephropathy: A Prospective, Single-Center, Randomized Controlled Trial

NCT07404436 is registered in ClinicalTrials.gov with Beijing Friendship Hospital as lead sponsor.

NCT NCT07404436
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07404436 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy of Rivaroxaban for Thromboprophylaxis in Idiopathic Membranous Nephropathy: A Prospective, Single-Center, Randomized Controlled Trial
Lead sponsor
Beijing Friendship Hospital
Phase
Phase 4
Overall status
Recruiting
Start date
January 5, 2024
Completion date
December 31, 2026
Enrollment
134 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

idiopathic membranous nephropathy